Learn More
OBJECTIVES SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI. METHODS Hamsters were infected with either C. difficile BI1 (ribotype 027) or C. difficile 630(More)
  • 1